BMS-986126 是一种强效、选择性强且口服有效的 IRAK4 抑制剂(IC50 = 5.3 nM),可广泛抑制 MyD88 依赖性信号通路,并在 MRL/lpr 和 NZB/NZW 小鼠狼疮模型中表现出显著活性、抑制多种致病反应,因此可用于系统性红斑狼疮 (SLE) 等自身免疫性疾病的相关研究。
产品编号: MS-H99318 CAS No.: 1610017-20-3 分子式: C22H25FN6O2 分子量: 424.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

BMS-986126 是一种强效、选择性强且口服有效的 IRAK4 抑制剂(IC50 = 5.3 nM),可广泛抑制 MyD88 依赖性信号通路,并在 MRL/lpr 和 NZB/NZW 小鼠狼疮模型中表现出显著活性、抑制多种致病反应,因此可用于系统性红斑狼疮 (SLE) 等自身免疫性疾病的相关研究。

生物实验数据

生物活性 BMS-986126 is a potent, selective, and orally active IRAK4 inhibitor (IC50 = 5.3 nM) that broadly inhibits MyD88-dependent signaling pathways and exhibits significant activity in MRL/lpr and NZB/NZW mouse lupus models by suppressing multiple pathogenic responses, making it useful for research on autoimmune diseases such as systemic lupus erythematosus (SLE).
IC50 & Target

IRAK4

5.3 nM (IC50)

体外研究
(In Vitro)

BMS-986126 对人外周血单核细胞 (PBMC) 中多种 MyD88 依赖性 TLR (TLR2/5/7/9) 表现出相似的纳摩尔级效力 (IC50:135-456 nM),并能有效抑制 NF-κB 调节的 IL-6 和 I 型干扰素 (IFN-α) 反应,甚至抑制 IL-1β 和 IL-18 诱导的细胞因子。
BMS-986126 对 MyD88 非依赖性激动剂 TLR3 和 TNF-α 诱导的细胞因子产生无显著影响。
BMS-986126 (0-2 μM,30 分钟) 剂量依赖性地抑制人 PBMC 中 TLR2 和 TLR4 下游的 IKKα/β 和 ERK 以及 TLR7 下游的 ERK 的磷酸化。
BMS-986126 在抑制健康供体和系统性红斑狼疮患者 PBMC 中 TLR7/9 诱导的干扰素反应基因表达 (例如 IFIT1) 方面表现出同等效力。
BMS-986126 (5 μM,30 分钟) 可广泛逆转人 PBMC 中 TLR7 激活诱导的基因表达谱,其中相当一部分被抑制的基因是经典的干扰素刺激基因。
BMS-986126 (16-80 nM,30 分钟) 与 Prednisolone (MS-H48362) 联用可协同抑制人 PBMC 中 TLR9 诱导和流感病毒诱导的 IFIT1 表达,其抑制作用显著强于单药。

Western Blot Analysis

Cell Line: PBMCs
Concentration: 0, 0.07, 0.22, 0.67, 2 μM
Incubation Time: 30 min
Result: Inhibited LPS-induced IKKα/b and ERK phosphorylation.
Inhibited TLR2-induced IKKα/b and ERK phosphorylation.
Robustly inhibit Gardiquimod (MS-F53796)-induced ERK phosphorylation
体内研究
(In Vivo)

BMS-986126 (0.1-3 mg/kg,口服,单次给药,在 LTA/CpG-ODN/Gardiquimod 前 30 分钟给药) 可抑制小鼠体内多种MyD88依赖性 TLR (TLR2/7/9) 下游的细胞因子生成。
BMS-986126 (0.3-10 mg/kg,口服,每日一次,持续 6 天或 8 周) 可显著抑制自发性 (MRL/lpr 和 NZB/NZW) 小鼠狼疮模型中的疾病活动。

Animal Model: Female BALB/c mice intraperitoneally injected with LTA (25 mg/kg)
Dosage: 0.1, 0.3, 1.0, and 3.0 mg/kg
Administration: p.o., single dose 30 min pre-LTA
Result: Dose-dependently suppressed LTA-induced IL-6 plasma levels, with maximal inhibition observed at the top dose of 3 mg/kg.
Animal Model: Male C57BL/6 mice (12-week-old) intravenously injected with CpG-ODN (2.5 μg)
Dosage: 1 and 3 mg/kg
Administration: p.o., single dose 30 min pre-CpG-ODN
Result: Strongly suppressed IFN-α at both 2 and 8 h after CpG-ODN challenge.
No IFN-α was detected in any group at 24 h after CpG-ODN challenge.
Animal Model: Male C57BL/6 mice (12-week-old) intraperitoneally injected with Gardiquimod (5 mg/kg)
Dosage: 1 and 3 mg/kg
Administration: p.o., single dose 30 min pre-Gardiquimod
Result: Dose-dependently suppressed both IFN-α and IL-6 production at both 2 and 8 h after Gardiquimod challenge.
Animal Model: Male MRL/lpr mice (12-14 weeks old)
Dosage: 0.3, 1, 3, and 10 mg/kg
Administration: p.o., daily for 8 weeks
Result: Dose-dependently suppressed biomarkers of kidney damage and systemic inflammation.
Showed very strong inhibition of kidney damage end points, including reduction of absolute protein levels in the urine, urine NGAL levels, and serum blood urea nitrogen.
Demonstrated significant protection of all end points at 1 mg/kg.
Dose-dependently suppressed dsDNA-specific autoantibody titers, as well as plasma levels of IL-10 and IL-12p40.
Significantly suppressed the percentage of splenic IFN-α+ pDCs at both the 1 and 10 mg/kg doses.
Suppressed IL-6 production by splenic CD11b+ myeloid cells.
All but the lowest dose inhibited IgG deposition in the kidney.
Dose-dependently suppressed histopathology in the kidney.
Animal Model: Male C57BL/6 mice induced by Imiquimod (MS-W79117)
Dosage: 0.3, 1, 3, and 10 mg/kg
Administration: p.o., daily for 6 days
Result: Dose-dependently suppressed skin thickening, scaling, erythema, and spleen weight gain.
Significantly inhibited skin histopathology at 3 and 10 mg/kg.
Maintained its plasma levels above the mouse in vitro whole blood LTA-induced IL-6 IC50 value for 24 h.
Maintained its concentrations above the mouse whole blood IC50 value (LTA-induced IL-6 IC50) for 8-12 h out of the day.
Animal Model: Female NZB/NZW mice (12-14 weeks old)
Dosage: 0.3, 1, 3, and 10 mg/kg
Administration: p.o., daily for 25 weeks
Result: Strongly suppressed biomarkers of kidney damage at all doses tested, including urine protein levels and urine levels of NGAL.
Dose-dependently suppressed systemic end points including dsDNA-specific autoantibody titers and plasma IL-12p40 levels.
Inhibited the percentage of splenic IFN-α+ pDCs.
Significantly inhibited the expression of the IFN response gene IFIT1 in peripheral blood.
Dose-dependently inhibited IgG deposition in the kidney.
Significantly suppressed histopathology in the kidneys with profound effects on glomerular damage and tubular damage subscores.

化学信息

分子量 424.47
分子式 C22H25FN6O2
CAS No. 1610017-20-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础